IL199077A - Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material - Google Patents

Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material

Info

Publication number
IL199077A
IL199077A IL199077A IL19907709A IL199077A IL 199077 A IL199077 A IL 199077A IL 199077 A IL199077 A IL 199077A IL 19907709 A IL19907709 A IL 19907709A IL 199077 A IL199077 A IL 199077A
Authority
IL
Israel
Prior art keywords
alpha
beta
quinolineethanol
naphthalenyl
dimethylamino
Prior art date
Application number
IL199077A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL199077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL199077A publication Critical patent/IL199077A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL199077A 2006-12-05 2009-06-02 Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material IL199077A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
IL199077A true IL199077A (en) 2016-09-29

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199077A IL199077A (en) 2006-12-05 2009-06-02 Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material

Country Status (34)

Country Link
US (1) US8546428B2 (OSRAM)
EP (1) EP2086940B1 (OSRAM)
JP (2) JP2010511663A (OSRAM)
KR (1) KR101514700B1 (OSRAM)
CN (2) CN105012303A (OSRAM)
AP (1) AP2498A (OSRAM)
AR (1) AR064149A1 (OSRAM)
AU (1) AU2007328945B2 (OSRAM)
BR (1) BRPI0719693A2 (OSRAM)
CA (1) CA2668512C (OSRAM)
CL (1) CL2007003472A1 (OSRAM)
CY (1) CY1113594T1 (OSRAM)
DK (1) DK2086940T3 (OSRAM)
EA (1) EA017091B9 (OSRAM)
ES (1) ES2387923T3 (OSRAM)
HK (1) HK1214513A1 (OSRAM)
HR (1) HRP20120639T1 (OSRAM)
IL (1) IL199077A (OSRAM)
JO (1) JO2973B1 (OSRAM)
ME (1) ME01456B (OSRAM)
MX (1) MX2009005909A (OSRAM)
MY (1) MY148844A (OSRAM)
NO (1) NO342773B1 (OSRAM)
NZ (1) NZ576485A (OSRAM)
PE (1) PE20081350A1 (OSRAM)
PL (1) PL2086940T3 (OSRAM)
PT (1) PT2086940E (OSRAM)
RS (1) RS52408B (OSRAM)
SI (1) SI2086940T1 (OSRAM)
TW (1) TWI417098B (OSRAM)
UA (1) UA97813C2 (OSRAM)
UY (1) UY30762A1 (OSRAM)
WO (1) WO2008068231A1 (OSRAM)
ZA (1) ZA200903907B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
FI3250182T3 (fi) * 2015-01-27 2023-06-28 Janssen Pharmaceutica Nv Dispergoituvia koostumuksia
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
DK3971177T3 (da) * 2016-07-20 2024-07-15 Novartis Ag Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
SI3943070T1 (sl) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv, Dolgo delujoče formulacije bedakilina
JP7654544B2 (ja) * 2018-12-13 2025-04-01 マンカインド コーポレイション ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
IL122026A0 (en) * 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置

Also Published As

Publication number Publication date
EA017091B9 (ru) 2014-10-30
UA97813C2 (uk) 2012-03-26
MX2009005909A (es) 2009-06-16
JP2015028049A (ja) 2015-02-12
CA2668512C (en) 2015-03-24
AP2009004870A0 (en) 2009-06-30
NO20092535L (no) 2009-08-06
US20100028428A1 (en) 2010-02-04
TW200838527A (en) 2008-10-01
KR20090087020A (ko) 2009-08-14
TWI417098B (zh) 2013-12-01
WO2008068231A1 (en) 2008-06-12
HK1214513A1 (zh) 2016-07-29
JO2973B1 (en) 2016-03-15
SI2086940T1 (sl) 2012-09-28
AP2498A (en) 2012-10-19
US8546428B2 (en) 2013-10-01
HRP20120639T1 (hr) 2012-08-31
UY30762A1 (es) 2008-07-03
AR064149A1 (es) 2009-03-18
KR101514700B1 (ko) 2015-04-24
EA017091B1 (ru) 2012-09-28
EA200970532A1 (ru) 2009-10-30
EP2086940A1 (en) 2009-08-12
ES2387923T3 (es) 2012-10-04
JP5894239B2 (ja) 2016-03-23
MY148844A (en) 2013-06-14
RS52408B (sr) 2013-02-28
AU2007328945A1 (en) 2008-06-12
CA2668512A1 (en) 2008-06-12
PT2086940E (pt) 2012-08-09
ME01456B (me) 2014-04-20
CL2007003472A1 (es) 2008-08-22
NZ576485A (en) 2012-01-12
ZA200903907B (en) 2013-08-28
JP2010511663A (ja) 2010-04-15
CN105012303A (zh) 2015-11-04
DK2086940T3 (da) 2012-08-20
PL2086940T3 (pl) 2012-10-31
EP2086940B1 (en) 2012-05-16
AU2007328945B2 (en) 2014-04-03
PE20081350A1 (es) 2008-09-18
BRPI0719693A2 (pt) 2013-12-24
NO342773B1 (no) 2018-08-06
CY1113594T1 (el) 2016-06-22
CN101547904A (zh) 2009-09-30

Similar Documents

Publication Publication Date Title
IL199077A (en) Oral Pharmaceutical Preparation Containing Fumarate Salt of (Alpha S, Beta R) -6- Bromo-Alpha- [2- (Dimethylamino) Ethyl] -2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolinethanol , Uses and process for making active material
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
TW200833663A (en) Therapeutic agents
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
PL1799633T3 (pl) Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu do stosowania jako składnik aktywny w kompozycjach farmaceutycznych
IL197442A (en) Therapeutic compositions containing glp-elp fusion proteins and their use in preparing a drug
IL205872A (en) Process for the preparation of compounds 2- [4- (3- or 2-fluorobenzyloxy) benzylamino] high-purity propanamide, medicinal preparations containing them, and their use in the preparation of drugs
UA90786C2 (uk) Похідні бензамідів і гетероаренів
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
GEP20084468B (en) Gamma-d crystalline form of ivabradin hydrochloride, process for its preparation and pharmaceutical compositions containing it
WO2008053446A3 (en) Benzoxazepine compounds, their preparation and use
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
IL212966A (en) Pyrazole-1-yl-methyl-cyclohexyl-acetic acid compounds, pharmaceutical preparations containing them, use of pharmaceutical preparation compounds and compounds for use in treatment method
SG130111A1 (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
EP2168586A4 (en) ACTIVE AGENT, REMEDY, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF PATIENTS WITH DENTAL SYNDROME
WO2009057138A3 (en) Controlled release pharmaceutical compositions of tolterodine
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
IL177402A0 (en) Composition for oral administration of tamsulosin hydrochloride
ZA200901083B (en) Modified release pharmaceutical composition of bupropion hydrochloride
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
TW201129557A (en) Pharmaceutical composition for oral administration
WO2008120617A1 (ja) クローン病に伴う腸管狭窄の進展抑制用医薬組成物
WO2010023693A3 (en) Controlled release compositions of ropinirole

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed